Interní Med. 2015; 17(3): 147-149
Optimizing of heart failure pharmacotherapy - role of ivabradin
- Ambulance srdečního selhání, Nemocnice Na Homolce, Praha
The aim of the chronic heart failure therapy is to reduce risk of death and risk of heart failure hospitalization without affecting quality of life.
Beta-blockers are considered to be cornerstones of medical therapy. In many patients, increased heart rate persists despite the maximal
tolerated beta-blocker dose. A case study shows, that optimizing of heart failure pharmacotherapy with ivabradin added to beta-blocker
might decrease heart rate and increase tolerability to load, together with antiremodelling effect as assessed by the drop of NT-proBNP level.
Keywords: chronic heart failure, pharmacotherapy, optimization, ivabradin
Published: June 1, 2015 Show citation
References
- Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patiens with suspected or proven coronary artery disease Eur Heart J 2005; 26: 967-974.
Go to original source... 
Go to PubMed... - Fox K, Ford I, Steg PG, et al on behalf of BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patiens with coronary artery dinase and left-ventricular systolic dysfunction: a subgroup analysis of a randomised controlled trial. Lancet 2008; 372: 817-821. Go to original source... Go to PubMed...
- Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patiens with systolic chronic heart silure receiving betablockers Am J Cardiol 2008; 101: 865-869. Go to original source... Go to PubMed...
- Špinar J, Vítovec J, Hradec J, Málek I, et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání České kardiologické společnosti 2011. Vnitř Lék 2012; 58(Suppl1): 1S4-1S40.
- Swedberg K, Komajda M, Bohm M, et al. Ivabradin and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376: 875-885. Go to original source... Go to PubMed...
- Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011; DOI: 10.1093/eurheartj/ehr343. Go to original source... Go to PubMed...
- Tardif JC, O'Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: Results from the SHIFT echocardiography substudy. Eur Heart J 2011; DOI: 10.1093/eurheartj/ehr311. Go to original source... Go to PubMed...
- Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial) Int J Cardiol 2011; 151(2): 218-224. Go to original source... Go to PubMed...
- Böhm M, Swedberg K, KOmajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894. Go to original source... Go to PubMed...
- Maeda K, Tsutamoto T, Wada A, et al. High Levels of Plasma Brain Natriuretic Peptide and Interleukin-6 After Optimized Treatment for Heart Failure Are Independent Risk Factors for Morbidity and Mortality in Patients With Congestive Heart Failure JACC 2000; 36(5): 1587-1593. Go to original source... Go to PubMed...